Galapagos and Cancer Research Technology form new collaboration
Genomics-based drug discovery company Galapagos, of Mechelen, Belgium, and Cancer Research Technology (CRT), a specialist in oncology drug discovery, owned by Cancer Research UK, are to collaborate in anti-cancer drug discovery research.
Genomics-based drug discovery company Galapagos, of Mechelen, Belgium, and Cancer Research Technology (CRT), a specialist in oncology drug discovery, owned by Cancer Research UK, are to collaborate in anti-cancer drug discovery research.
Galapagos' service division BioFocus will perform medicinal chemistry services on a series of CRT anti-cancer drug programmes. In return, CRT will fund the work of four BioFocus scientists throughout 2006.
'CRT has succeeded in forming a number of collaborative anti-cancer programmes with academic and commercial partners alike,' said Tony Raynham, CRT's head of medicinal chemistry. 'Our relationship with BioFocus, in conjunction with existing in-house R&D resource, will ensure that these programmes are advanced rapidly through early-stage development, thereby creating robust licensing opportunities and cancer patient benefit.'